This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abiomed (ABMD) Q2 Earnings Beat, Impella Maintains Momentum
by Zacks Equity Research
Abiomed's (ABMD) flagship Impella sees a solid Q2; fiscal 2019 outlook raised.
Bruker (BRKR) Q3 Earnings Surpass Estimates, Guidance Up
by Zacks Equity Research
We are upbeat about Bruker's (BRKR) current focus on product development through higher R&D.
Teleflex (TFX) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
Teleflex (TFX) consistently rides high on a robust uptick in revenues, backed by stable segmental growth and solid geographical expansions.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) Q3 results on solid uptake of Omnipod system in the United States. It is also gaining from pursuing direct European operations.
Bio-Rad (BIO) Earnings Miss Estimates in Q3, Revenues Beat
by Zacks Equity Research
Bio-Rad's (BIO) solid revenue growth in geographies like North America, China and Asia Pacific in Q3 buoys optimism.
Intuitive Surgical (ISRG) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed the most recent trading day at $518.61, moving -0.49% from the previous trading session.
IDEXX Laboratories (IDXX) Beats on Q3 Earnings, EPS View Up
by Zacks Equity Research
IDEXX Laboratories' (IDXX) stellar performance in Q3 reflects strong sales at the CAG business.
PerkinElmer (PKI) Misses on Q3 Earnings, Slashes EPS View
by Zacks Equity Research
Perkinelmer (PKI) gains from segmental performances in Q3; lowers 2018 EPS view.
Accuray (ARAY) Q1 Loss Wider Than Expected, Gross Orders Rise
by Zacks Equity Research
Accuray's (ARAY) flagship Radixact System drives Q1 results; strong EBITDA guidance instils hope.
Express Scripts (ESRX) Tops Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Express Scripts' (ESRX) Q3 results hurt by year-over-year decline in adjusted network claims, thanks to the loss of certain public sector clients.
Baxter (BAX) Earnings Beat, Revenues Lag Estimates in Q3
by Zacks Equity Research
Baxter (BAX) gains from Renal Care and Advanced Surgery units in Q3; APAC sales soft.
Cardiovascular Systems' (CSII) Q1 Loss Wider Than Expected
by Zacks Equity Research
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q1.
NextGen Healthcare (NXGN) Beats on Q2 Earnings, Lags Revenues
by Zacks Equity Research
NextGen Healthcare (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q2; lowers fiscal 2019 view.
Fresenius Medical (FMS) Beats on Q3 Earnings, Lags Revenues
by Zacks Equity Research
Lower North America sales hurt Fresenius Medical's (FMS) Q3 results. Care Coordination margin improves significantly.
Amedisys (AMED) Tops Earnings and Revenue Estimates in Q3
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues in Q3.
Ecolab (ECL) Misses on Q3 Earnings & Revenues, Lowers View
by Zacks Equity Research
Ecolab (ECL) misses estimates despite strong growth in Global Industrial and Global Institutional; 2018 guidance dull.
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year revenue growth in Q3 and operating margin expansion are encouraging.
Top Stock Reports for Microsoft, Alphabet, Bank of America & Wells Fargo
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Microsoft (MSFT), Alphabet (GOOGL), Bank of America (BAC) and Wells Fargo (WFC).
Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
Intuitive Surgical (ISRG) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $506.93 in the latest trading session, marking a -0.88% move from the prior day.
Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Strong performance in the Instruments & Accessories and Systems segments drive Intuitive Surgical's (ISRG) top line in Q3.
Trump vs. The Fed and PayPal, Intuitive Surgical Earnings Previews
by Ryan McQueeney
Ryan McQueeney discusses the Fed's decision to remain hawkish amid criticism from President Trump. He also recaps earnings results from Travelers, Blackstone, and Philip Morris. Later, he is joined by Dave Bartosiak to preview upcoming reports from PayPal and Intuitive Surgical.
This Week's Hottest Earnings Charts
by Tracey Ryniec
Wall Street will be tuning into the earnings reports on these 5 companies this week.
Here's Why You Should Invest in GNC Holdings (GNC) Right Now
by Zacks Equity Research
GNC Holdings (GNC) registers strong performance in e-commerce business and International segment. In fact, the company is putting an all-out effort to strengthen its international presence.
Will Instruments Drive Intuitive Surgical (ISRG) Q3 Earnings?
by Zacks Equity Research
Strong prospects in the Instruments and Accessories segment to drive Intuitive Surgical???s (ISRG) top line in the third quarter of 2018.